<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01689987</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00008296</org_study_id>
    <secondary_id>NCI-2012-01754</secondary_id>
    <secondary_id>CR00022154</secondary_id>
    <secondary_id>MR00041096</secondary_id>
    <secondary_id>IRB00008296</secondary_id>
    <secondary_id>P30CA069533</secondary_id>
    <nct_id>NCT01689987</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase I Dose Escalation Study of Hydroxychloroquine With Infusional Cyclophosphamide, Pulse Dexamethasone and Rapamycin in Patients With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of hydroxychloroquine when given
      together with cyclophosphamide, dexamethasone, and sirolimus in treating patients with
      multiple myeloma that has come back after a period of improvement or does not respond to
      treatment. Biological therapies, such as hydroxychloroquine, may stimulate the immune system
      in different ways and stop cancer cells from growing. Sirolimus may stop the growth of cancer
      cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy,
      such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of
      cancer cells, either by killing the cells, stopping them from dividing, or by stopping them
      from spreading. Giving hydroxychloroquine together with sirolimus, cyclophosphamide, and
      dexamethasone may be a better treatment for multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the maximum tolerated dose (MTD) of hydroxychloroquine (HCQ) in combination
      with rapamycin (sirolimus) and infusional cyclophosphamide and pulse dexamethasone (cy/dex)
      for patients with relapsed/ refractory multiple myeloma.

      SECONDARY OBJECTIVES:

      I. To evaluate biological activity and efficacy of the combination of cyclophosphamide,
      dexamethasone, rapamycin and hydroxychloroquine in patients with relapsed/refractory multiple
      myeloma.

      II. To determine whether this treatment regimen results in mammalian target of rapamycin
      (mTOR) and autophagy inhibition in primary myeloma cells during therapy and if this
      corresponds with treatment responses.

      OUTLINE: This is a dose-escalation study of hydroxychloroquine.

      Patients receive hydroxychloroquine orally (PO) daily on days 1-28 (days 5-28 of course 1),
      sirolimus PO on days -2 to 4, and cyclophosphamide intravenously (IV) continuously and
      dexamethasone PO on days 1-4. Treatment repeats every 28 days for up to 12 courses in the
      absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up for 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD of hydroxychloroquine defined as the highest dose at which 0/6 or 1/6 subjects experience a dose limiting toxicity (DLT) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0</measure>
    <time_frame>56 days</time_frame>
    <description>Incidence of DLTs will be tabulated for each dose level. Summarized using descriptive statistics or frequency distributions, as appropriate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of overall response</measure>
    <time_frame>Time that measurement criteria are met for response (whichever status is recorded first) until the first date that recurrent or progressive disease is objectively documented, assessed up to 12 months</time_frame>
    <description>Will be summarized by 25th, 50th (median), and 75th percentile along with 95% confidence intervals using Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myeloma response (stringent complete response, complete response, very good partial response, partial response, stable disease, and progressive disease), as assessed by the International Myeloma Working Group</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Presented with two-sided 95% exact binomial confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Time from start of treatment to time of progression or death, whichever occurs first, assessed up to 12 months</time_frame>
    <description>Will be summarized by 25th, 50th (median), and 75th percentile along with 95% confidence intervals using Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>Time from the first day of therapy until the time that measurement criteria are met for response, assessed up to 12 months</time_frame>
    <description>Will be summarized by 25th, 50th (median), and 75th percentile along with 95% confidence intervals using Kaplan-Meier method.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean percentage of p70S6 myeloma cells</measure>
    <time_frame>Up to day 5 of course 2</time_frame>
    <description>The mean percentage of p70S6 myeloma cells and the number of autophagic vesicles per bone marrow plasma cells will be compared between responders and non-responders using two-sample test if the data follows normal distribution or if the data does not follow normal distribution, transformation or non-parametric method will be considered.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of autophagic vesicles per bone marrow plasma cells</measure>
    <time_frame>Up to day 5 of course 2</time_frame>
    <description>The mean percentage of p70S6 myeloma cells and the number of autophagic vesicles per bone marrow plasma cells will be compared between responders and non-responders using two-sample test if the data follows normal distribution or if the data does not follow normal distribution, transformation or non-parametric method will be considered.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Recurrent Plasma Cell Myeloma</condition>
  <condition>Refractory Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment (HCQ, sirolimus, cy/dex)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive hydroxychloroquine PO daily on days 1-28 (days 5-28 of course 1), sirolimus PO on days -2 to 4, and cyclophosphamide IV continuously and dexamethasone PO on days 1-4. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (HCQ, sirolimus, cy/dex)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (HCQ, sirolimus, cy/dex)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>Visumetazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (HCQ, sirolimus, cy/dex)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (HCQ, sirolimus, cy/dex)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (HCQ, sirolimus, cy/dex)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (HCQ, sirolimus, cy/dex)</arm_group_label>
    <other_name>AY 22989</other_name>
    <other_name>RAPA</other_name>
    <other_name>Rapamune</other_name>
    <other_name>RAPAMYCIN</other_name>
    <other_name>SILA 9268A</other_name>
    <other_name>WY-090217</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed multiple myeloma

          -  Documented relapse or persistent disease after at least 1 prior therapy containing
             both bortezomib and lenalidomide; or at least 2 prior therapies containing bortezomib
             in one and lenalidomide in the other, or if intolerant of bortezomib and/or
             lenalidomide; prior autologous and allogeneic bone marrow transplantation are allowed

          -  Need for further treatment for myeloma, as determined by the patient's treating
             physician; this is defined as progression of clinical features (worsening anemia,
             renal function, bone disease, hypercalcemia, recurrent infections, and constitutional
             symptoms) OR biochemical progression (increasing M-spike in serum or urine, involved
             serum or urine free light chain over 2 consecutive time points greater than 4 weeks
             apart)

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2 (Karnofsky &gt;= 60%)

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Birth control is required with full barrier contraceptives or complete abstinence for
             the duration of time receiving therapy and for 6 months after completing the last drug
             taken

          -  The need for further treatment: this is defined as progression of clinical features
             (worsening anemia, renal function, bone disease, hypercalcemia, recurrent infections,
             and constitutional symptoms) OR biochemical progression (increasing M-spike in serum
             or urine, involved serum or urine free light chain over 2 consecutive time points
             greater than 4 weeks apart)

        Exclusion Criteria:

          -  History of allergic reactions to compounds of similar chemical or biological
             composition to rapamycin or hydroxychloroquine

          -  Patients may not take any of the following medications while on study, but will be
             considered eligible if medication is discontinued at least 72 hours (hrs) prior to
             first dose of Rapamycin:

               -  Carbamazepine

               -  Rifabutin

               -  Rifampin

               -  Rifapentine

               -  St. John's wort

               -  Clarithromycin

               -  Cyclosporine

               -  Diltiazem

               -  Erythromycin

               -  Itraconazole

               -  Fluconazole

               -  Ketoconazole

               -  Telithromycin

               -  Verapamil

               -  Voriconazole

               -  Posaconazole

          -  Known macular degeneration or retinopathy (diabetic or otherwise), porphyria, or
             psoriasis (well-controlled psoriasis allowed provided under the care of a specialist
             who agrees to monitor the patient for exacerbations)

          -  Absolute neutrophil count (ANC) =&lt; 1.0 x 10^9/L

          -  Platelets =&lt; 50 x 10^9/L for any reason

          -  Serum creatinine &gt;= 2.5 mg/dL

          -  Total or direct bilirubin &gt;= 2.0 mg/dL

          -  Transaminases 2 x the upper limit of normal

          -  Fasting glucose &gt;= 200 mg/dL

          -  Serum potassium &lt; 3.4 mmol/l

          -  Serum phosphorus &lt; 2.4 mg/dl

          -  Other conditions that would require therapy with hydroxychloroquine, including but not
             limited to, any of the following:

               -  Systemic lupus

               -  Rheumatoid arthritis

               -  Porphyria cutanea tarda

               -  Malaria treatment or prophylaxis

          -  Evidence of other active malignancy, except:

               -  Basal cell or squamous cell carcinoma of the skin

               -  Treated carcinoma in situ

          -  Uncontrolled intercurrent illness including, but not limited to, any of the following:

               -  Uncontrolled ongoing infection

               -  Human immunodeficiency virus (HIV)

               -  Hepatitis B infection

               -  Known glucose-6-phosphate dehydrogenase (G6PD) deficiency

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Uncontrolled cardiac arrhythmia

               -  Psychiatric illness or social situations that would limit compliance with study
                  requirements

               -  Active graft-versus-host disease (GvHD)

          -  Inability to understand or unwillingness to sign the informed consent document

          -  Concurrent anti-myeloma therapy within:

               -  7 days of prior corticosteroids

               -  14 days of prior antimyeloma agents, including thalidomide or lenalidomide

               -  28 days of a different investigational regimen

               -  14 days of any radiation

          -  Women of child-bearing who are unwilling or unable to use an acceptable method to
             avoid pregnancy for the entire study period and for up to 30 days after the last dose
             of study drug

          -  Women who are pregnant or breastfeeding

          -  History of G6PD deficiency

          -  Known history of HIV infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emma Scott</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2012</study_first_submitted>
  <study_first_submitted_qc>September 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2012</study_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Emma Scott</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

